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OBJECTIVE—Anti-tissue transglutaminase (TG2) antibodies
are the serological marker of celiac disease. Given the close
association between celiac disease and type 1 diabetes, we
investigated the production and deposition of anti-TG2 antibod-
ies in the jejunal mucosa of type 1 diabetic children.
RESEARCH DESIGN AND METHODS—Intestinal biopsies
were performed in 33 type 1 diabetic patients with a normal
mucosal architecture: 14 had high levels (potential celiac disease
patients) and 19 had normal levels of serum anti-TG2 antibodies.
All biopsy specimens were investigated for intestinal deposits of
IgA anti-TG2 antibodies by double immunoﬂuorescence. In addi-
tion, an antibody analysis using the phage display technique was
performed on the intestinal biopsy specimens from seven type 1
diabetic patients, of whom four had elevated and three had
normal levels of serum anti-TG2 antibodies.
RESULTS—Immunoﬂuorescence studies showed that 11 of 14
type 1 diabetic children with elevated levels and 11 of 19 with
normal serum levels of anti-TG2 antibodies presented with
mucosal deposits of such autoantibodies. The phage display
analysis technique conﬁrmed the intestinal production of the
anti-TG2 antibodies; however, whereas the serum-positive type 1
diabetic patients showed a preferential use of the VH5 antibody
gene family, in the serum-negative patients the anti-TG2 antibod-
ies belonged to the VH1 and VH3 families, with a preferential use
of the latter.
CONCLUSIONS—Our ﬁndings demonstrate that there is intes-
tinal production and deposition of anti-TG2 antibodies in the
jejunal mucosa of the majority of type 1 diabetic patients.
However, only those with elevated serum levels of anti-TG2
antibodies showed the VH usage that is typical of the anti-TG2
antibodies that are produced in patients with celiac disease.
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nsulin-dependent diabetes (type 1 diabetes) is char-
acterized by an autoimmune destruction of the pan-
creatic islet -cells that results in a loss of insulin
secretion. T-cells that are reactive against speciﬁc
-cell antigens inﬁltrate the endocrine pancreas and de-
stroy the -cells (1). Both genetic susceptibility and envi-
ronmental factors contribute to the pathogenesis of type 1
diabetes.
Mounting evidence suggests that the gut immune system
is involved in the development of autoimmune diabetes.
An inﬂammatory state has been demonstrated to be
present in the structurally normal intestine of patients
with type 1 diabetes (2,3), and the abnormal intestinal
permeability that has been found in these patients could
represent a contributing factor (4). Higher intestinal levels
of proinﬂammatory cytokines, such as interleukin-1 and
also interleukin-4, have been reported (3). Recently, we
used immunohistochemistry to demonstrate signs of acti-
vated cell-mediated mucosal immunity in the lamina pro-
pria of the small intestine of type 1 diabetic patients (5);
furthermore, the epithelial compartment shows signs of
increased inﬁltration by CD3
 and 
 cells (5).
Type 1 diabetes has been found to be associated with
other autoimmune diseases, including celiac disease (6–
8). Celiac disease is an immune-mediated disease that is
triggered by the ingestion of gliadin and other toxic
prolamines. It is characterized by a dysregulated immune
response at the gut level (9) that results in enteropathy.
Several autoantibodies, of which anti-tissue transglutami-
nase (TG2) autoantibodies are the most frequently ob-
served, are present in the serum of patients with untreated
celiac disease. Several studies that have used phage dis-
play libraries suggest that these autoantibodies are primar-
ily produced in the small bowel mucosa and that there is a
preferential use of heavy-chain variable regions belonging
to the VH5 gene family in patients with celiac disease (10).
At the mucosal level, anti-TG2 antibodies are found to be
deposited on extracellular TG2 (11).
It is possible that type 1 diabetes and celiac disease are
more than simply associated; gluten may also have a
causative role in type 1 diabetes. This hypothesis has been
suggested by the observation of an altered intestinal
immune response to gluten in type 1 diabetes. In type 1
diabetic patients, we reported that there is local mucosal
recruitment of lymphocytes after rectal instillation of
gliadin (12); we also observed an enhanced immune re-
sponse to gliadin after in vitro gluten challenge in biopsy
specimens from type 1 diabetic patients negative for
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1578 DIABETES, VOL. 58, JULY 2009serum anti-human TG2 antibodies (5). These subjects with
signs of a deranged immune response to gliadin may be
considered potential celiac disease patients (13); in fact,
some of the type 1 diabetic patients who are negative for
celiac disease–associated autoantibodies may later be-
come seropositive and may eventually develop frank en-
teropathy (14).
It has recently been shown that speciﬁc celiac disease
autoantibodies against TG2 are deposited in the normal
jejunal mucosa before they can be detected in the circu-
lation and that their deposition precedes the gluten-in-
duced jejunal lesion (15). This ﬁnding raises the possibility
that the anti-TG2 antibodies might be located only at the
small mucosal level in some type 1 diabetic patients.
In this study, we investigated the production and depo-
sition of anti-TG2 autoantibodies in the small intestinal
mucosa of type 1 diabetic children, irrespective of the
presence of this autoantibody in their serum, with the aim
of elucidating both the full spectrum of intestinal immu-
nological derangement in type 1 diabetes and the possible
relation with dietary gluten.
RESEARCH DESIGN AND METHODS
We studied 33 patients with type 1 diabetes who were consuming a gluten-
containing diet at the time of biopsy (median age 11 years, range 3–22 years).
All diabetic patients presented with normal jejunal architecture (stage T0/T1
according to the Marsh classiﬁcation modiﬁed by Oberhuber et al. [16]) and
were divided into two groups. Group A consisted of 14 patients with raised
serum levels of anti-TG2 antibodies (TG2
), and group B consisted of 19
patients with normal serum levels of speciﬁc celiac disease autoantibodies
(TG2
).
Twelve patients with untreated celiac disease, who had the diagnosis of
celiac disease on the basis of biopsy ﬁndings, high serum levels of anti-TG2
antibodies, and a positive response to a gluten-free diet, were included.
Twenty-eight subjects without celiac disease (ﬁnal diagnoses: iron deﬁciency
anemia, failure to thrive, gastroesophageal reﬂux, and recurrent abdominal
pain) were enrolled as the control group. Finally, 18 patients with inﬂamma-
tory bowel diseases (IBDs) and 9 with food allergies were enrolled to form an
additional control group that represented subjects with other conditions
characterized by gut inﬂammation.
The patients or the parents, where appropriate, gave their consent for the
biopsy sampling for the study. The University Ethics Committee approved the
use of the biopsy specimens in the study.
HLA typing. DNA extracted from blood samples was used to genotype for
HLA-II DQ2 and DQ8 haplotypes in the type 1 diabetic patients. In control
subjects, DNA was extracted from the biopsy specimens using PrepMan Ultra
Sample Preparation Reagent (Applied Biosystems). The Eu-DQ kit (Eurospi-
tal) was used for typing.
Jejunal biopsy and immunohistochemical analysis. Jejunal biopsy speci-
mens were obtained with a gastroscope from all of the patients. One fragment
was treated for histological analysis as described previously (17); a second
fragment was immediately embedded in an optimal cutting temperature
compound (BioOptica) and used in the detection of mucosal anti-TG2
antibody deposits. From seven of the diabetic patients, we obtained a third
fragment used for total RNA puriﬁcation. Immunohistochemistry, staining,
and morphometric analyses were performed as described previously (17).
Serum IgA anti-TG2 antibodies. Serum levels of IgA anti-TG2 antibodies
were determined by an enzyme-linked immunosorbent assay (ELISA) using a
kit based on recombinant human TG2 (Eu-tTg IgA kit; Eurospital) as de-
scribed previously (17). Values were considered positive if they were 7
arbitrary units/ml.
Intestinal anti-TG2 antibody IgA deposits by double immunoﬂuores-
cence and confocal analysis. All the of patients were investigated for
mucosal deposition of anti-TG2 antibody IgA. The technique described by
Korponay-Szabo et al. (11) was implemented with minor modiﬁcations.
Acetone-ﬁxed, 5-m frozen sections from each patient were examined by
double immunoﬂuorescence. After a 15-min preincubation with normal rabbit
serum (1:100; Dako), the sections were covered with a monoclonal mouse
antibody against guinea pig TG2 (CUB 7402, 1:200; NeoMarkers) for1ha t
room temperature in a humidiﬁed chamber. The sections were washed with
PBS and then incubated with a mixture of a ﬂuorescein isothiocyanate–
labeled rabbit antibody against human IgA (1:100; Dako) to detect (in green)
IgA and an R-phycoerythrin–labeled rabbit anti-mouse antibody (1:40; Dako)
to detect (in red) TG2 for 30 min in the dark. Finally, the sections were washed
in PBS and mounted with glycerol/PBS (1:10). The preparations were analyzed
with an Axioscope2 (Zeiss) microscope linked to an analysis image system
(Siemens). The colocalization of IgA mucosal deposits and TG2 resulted in a
yellow image at the ﬂuorescence microscope. The colocalization was con-
ﬁrmed by confocal microscopy (LSM510; Zeiss).
Phage display antibody libraries. Jejunal specimens from seven of the type
1 diabetic patients (three with normal levels of serum anti-TG2 autoantibod-
ies) were used for the puriﬁcation of tissue total RNA using TRIzol (Gibco Life
Technologies). cDNA was synthesized using random hexamers and Super-
Script III reverse transcriptase (Gibco Life Technologies). Two types of
intestinal B-lymphocyte phage display antibody libraries were constructed: an
IgA-VH5 gene family library and an IgA-whole gene family library. Ig VH5
regions were ampliﬁed using a speciﬁc V-region primer designed against the
ﬁrst 36 nucleotide bases of the VH5 family (18). Conversely, in the IgA whole
gene family library, VH and VL regions were ampliﬁed using a 3- and 5-primer
set as described previously (19). In the ﬁrst library, the PCR fragments were
gel puriﬁed and digested with XhoI and NheI (New England Biolabs) for
cloning into pDAN5 that had been modiﬁed with a VL region. In the latter
library, the PCR fragments were assembled in a single-chain fragment variable
(scFv) and digested with BsshII and NheI before cloning into the same vector.
The phage propagation was carried out in the strain Escherichia coli DH5F.
Rescue of phagemid particles was carried out as described previously (20).
Panning was performed by adding phages diluted in 2% nonfat milk/PBS to
immunotubes (Nunc) coated with puriﬁed recombinant human TG2 and
-gliadin (10 g/ml); the next steps were performed as reported previously
(18). After two rounds of panning, up to 93 individual clones were screened
for reactivity to the antigens. Phages from individual colonies were grown in
96-well plates (20). ELISAs were performed in microtiter plates coated with
antigens at 10 g/ml (18). Puriﬁed -gliadin was prepared as described
previously (21). Recombinant human TG2 was obtained by amplifying as
described previously (22). The V genes from the different anti-TG2 scFv clones
were sequenced (BigDye Terminator v3.1 Cycle Sequencing kit; Applied
Biosystems), and the VH gene families used were assessed by screening
against the V BASE (http://vbase.mrc-cpe.cam.ac.uk) database (23). Immu-
noﬂuorescence analysis with the different gene family anti-TG2 scFvs was
performed on histological sections of monkey esophagus (MeDiCa, Encini-
tas, CA).
Statistical analysis. A 	
2 test was used to compare percentage values. P 

0.05 was considered signiﬁcant.
RESULTS
Immunohistochemical analysis of type 1 diabetic je-
junal biopsy specimens. All of the type 1 diabetic
patients were observed to be HLA-DQ2 and/or -DQ8 posi-
tive. Signs of activated cell-mediated mucosal immunity
were present in approximately one-third of the type 1
diabetic subjects. In group A (TG2
), 4 of 14 patients (29%)
showed an increased density of CD25
 mononuclear cells
(4 CD25
cells/mm
2) in the lamina propria. Crypt epithe-
lium HLA-DR and intercellular adhesion molecule
(ICAM)-1 expressions were enhanced in 10 of 14 (71%) and
4 of 14 (29%) patients, respectively. In the epithelial
compartment, 6 of 14 patients (43%) presented with a
density of CD3
 intraepithelial lymphocytes (IELs) that
was higher than the cutoff (34 cells/mm epithelium), and
9 of 14 patients (64%) presented with a density of 
 IELs
that was higher than the cutoff (3.4 cells/mm epithe-
lium). In addition, 5 of 14 patients (36%) presented with
three or more of these above-mentioned altered values.
In group B (TG2
), 7 of 19 patients (37%) showed an
increased density of CD25
 mononuclear cells and 11 of
19 (58%) and 6 of 19 (31%) presented with increased
HLA-DR and ICAM-1 expression, respectively. With re-
spect to the epithelial compartment, 4 of 19 (21%) and 5 of
19 patients (26%) presented with an increased density of
CD3
 and 
 IELs, respectively (Table 1). Again, 5 of 19
patients (26%) presented with three or more of the above-
mentioned altered values. Only the percentage of subjects
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 IELs was signiﬁcantly
higher in group A than in group B (P 
 0.05).
Immunoﬂuorescence studies. Jejunal mucosa from
most of the control subjects without celiac disease
showed IgA antibodies, only inside the plasma cells and
the epithelial cells, which were labeled in green (Fig. 1A),
and only 4 of 28 subjects had patchy IgA mucosal deposits.
With regard to HLA status, 9 of the 28 (32%) control
subjects were HLA-DQ2 and/or -DQ8 positive, but only one
of the four individuals who were positive for mucosal
deposits was HLA-DQ2 positive. In the group of patients
with other inﬂammatory conditions of the gut, only three
of the subjects with IBD (16.6%) showed patchy deposits.
All 12 patients with untreated celiac disease showed
evident IgA deposits below the villous and crypt basement
membranes and around the mucosal vessels, correspond-
ing to the intestinal localization of TG2 (in red), apart from
the IgA inside the plasma cells. IgA-speciﬁc anti-TG2
antibody deposits appeared in yellow-orange because of
colocalization with TG2 (Fig. 1E).
Not unexpectedly, in group A (TG2
), 11 of the patients
(78%) were observed to have IgA anti-TG2 antibody mu-
cosal deposits that had a patchy distribution. Surprisingly,
we found that a high percentage of patients in group B
(TG2
) exhibited an IgA deposit–positive pattern; in fact,
11 of the 19 (58%) group B subjects showed IgA anti-TG2
antibody mucosal deposits (Fig. 1C). Four of these 11
patients (36%) presented with a density of 
 IELs that
was higher than the cutoff.
Most of the specimens with a patchy IgA deposit pat-
tern, all biopsy specimens from patients with untreated
celiac disease, and several normal biopsy specimens were
analyzed by confocal microscopy to further assess the
colocalization of IgA deposits with TG2 (Fig. 1,B, D, and
F). In all of the specimens, confocal analysis conﬁrmed the
observations described previously. All data are summa-
rized in Table 2.
Phage display antibody libraries. To further conﬁrm the
presence of anti-TG2 antibodies in the IgA deposits that
colocalized with TG2 in the jejunal specimens of type 1
diabetic patients, we performed an analysis based on
antibody phage display. In a previous article, we demon-
strated the prevalent use of the VH5 segment to make
antibodies against TG2 by the intestinal lymphocytes of
patients with celiac disease (10). Also, the reactivity to
TG2 was demonstrated to be restricted to the VH chain
alone because shufﬂing of the VL chain with unrelated
genes did not affect the antibody reactivity. This feature
was shared by the antibodies to TG2 from all of the
patients with celiac disease examined (18). For this rea-
TABLE 1
Immunohistochemical ﬁndings in the small intestine of type 1
diabetic patients enrolled in this study
Group A Group B P
CD3
 34/mm 6/14 (43) 4/19 (21) NS

 3.4/mm 9/14 (64) 5/19 (26) 
0.05
CD25
 4/mm
2 4/14 (29) 7/19 (37) NS
HLA-DR (/) 10/14 (71) 11/19 (58) NS
ICAM-1 (/) 4/14 (29) 6/19 (31) NS
Group A consisted of type 1 diabetic patients with elevated serum
levels of anti-TG2 antibodies (TG2
). Group B consisted of type 1
diabetic patients with normal serum levels of anti-TG2 antibodies
(TG2
). CD3
 and 
 IELs are expressed per millimeter of epithe-
lium; CD25
 cells are expressed per square millimeter of lamina
propria. The expression of crypt epithelial HLA-DR and the expres-
sion of lamina propria ICAM-1 were evaluated in terms of their
staining intensity and graded on an arbitrary scale of staining level,
where no staining, weak staining,   strong staining,
and   very strong staining. The data were analyzed by a 	
2
test. P 
 0.05 was considered signiﬁcant.
FIG. 1. A and B: Jejunal section from a subject without celiac disease.
It is a negative sample. In A, IgA deposits (in green) are detected only
inside plasma cells, whereas tissue transglutaminase (in red) is evident
around the crypts and in the subepithelial area. B: Confocal analysis
with a scatter plot of the image. In this plot, no area of colocalization
is evident around the diagonal of the Cartesian graphic. C and D:
Jejunal section from a type 1 diabetic patient with a high serum level
of anti-TG2 autoantibodies. In C, IgA deposits (in yellow-orange) are
present in a patchy distribution in the subepithelial area and around
mucosal vessels. These IgA/anti-TG2 antibody colocalization areas
have been analyzed by confocal microscopy. The related scatter plot is
shown in D, and the image of this area of colocalization is represented
by orange dots. E and F: Jejunal section from a patient with untreated
celiac disease with positive serum anti-TG2 antibodies and EMAs, in
which thick IgA anti-TG2 antibody deposits are evident just under the
superﬁcial epithelium and around the vessels (E). This subepithelial
area has been studied by confocal microscopy, and the related scatter
plot (F) shows an extensive area of IgA deposits/TG2 colocalization.
(A high-quality digital representation of this ﬁgure is available in the
online issue.)
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belonging to the VH5 family are a distinctive marker of
celiac disease. Thus, in the present study, a ﬁrst analysis
was performed on intestinal biopsy cDNAs by cloning the
VH5 family alone.
Seven IgA-VH5 gene family phage display libraries from
type 1 diabetic patients (three with normal levels of
anti-TG2 serum autoantibodies and four with elevated
levels, here reported as TG2
 and TG2
 type 1 diabetic
patients, respectively) were constructed using a phagemid
vector with resident VL genes compatible with TG2 recog-
nition (18). In all cases, the library diversity resulted in at
least 10
6 clones expressing human antibody fragments.
After two rounds of selection at a high level of stringency,
45 individual clones were analyzed for their reactivity to
recombinant human TG2 by a phage ELISA. In the libraries
obtained from the intestinal biopsy lymphocytes of TG2

patients, the number of positive clones ranged from 28 to
84% (Table 3). Conversely, using the three libraries con-
structed from the lymphocytes of TG2
 patients, the
number of clones recognizing TG2 was rather low, com-
prising between 0 and 6% of the tested clones. Because the
same antibody might be represented many times within
the selected clones, the diversity of the positive clones
was assessed by ﬁngerprinting the PCR-ampliﬁed VH5
region. The diversity was conﬁrmed for the large major-
ity of the clones, attesting to the polyclonal IgA re-
sponse to TG2.
Considering the high percentage of TG2
 patients who
were observed to have intestinal deposits of anti-TG2
antibodies, we decided to determine whether an anti-TG2
antibody response could be ascribed to non-VH5 antibod-
ies, which were not present in the ﬁrst version of the
antibody libraries. The whole antibody repertoire of the
seven type 1 diabetic patients and three control subjects
without celiac disease was cloned, assembling all of the
VH and VL gene family sequences. The results of the
library selections for TG2, reported in Table 4, show a
signiﬁcant number of clones that are positive for recom-
binant human TG2 isolated from the four libraries of type
1 diabetic patients with anti-TG2 serum antibodies (values
ranging from 46 to 88%). Unexpectedly, a comparable
result was obtained with the three libraries from the type
1 diabetic patients who did not have peripheral antibodies
to TG2, with a number of bacterial clones ranging from 71
to 86%. The antibody diversity, measured by ﬁngerprinting,
was high in all of the clusters, attesting to the humoral
response to TG2 involving different antibodies. Very few
positive clones were found in the control subjects without
celiac disease, with 0, 10, and 3 anti-TG2 antibody-positive
clones of 90 tested.
Furthermore, the whole IgA antibody libraries were
selected on native gliadin. Both TG2
 and TG2
 type 1
diabetic patients showed an elevated number of anti-
gliadin antibodies, with a positivity ranging from 53 to 97%
of the tested clones. In addition, the antibody diversity was
high in all cases. All data are summarized in Table 4.
Finally, assignment to the seven VH gene family mem-
bers of the positive antibodies to TG2 that were selected
from the whole libraries was determined by DNA sequenc-
ing. As reported in Fig. 2, 50% of the phage antibodies
from the type 1 diabetic patients belonged to the VH3
family, with minor usage of the other gene families. For
comparison, the antibodies to TG2 selected from the
phage display libraries from the intestinal B lymphocyte of
three patients with celiac disease that were constructed
previously were sequenced for gene family assignment. As
reported in Fig. 2, the results showed a more distributed
usage of the VH gene families with a stronger trend for
VH1 and VH5.
To further conﬁrm the speciﬁcity of the anti-TG2 anti-
bodies from the intestinal biopsy specimens of the type 1
diabetic patients, four soluble antibody fragments belong-
ing to VH3, VH1, and VH4 families were assayed for
anti-endomysium structure reactivity in monkey esopha-
gus specimens. As shown in Fig. 3, the VH5 antibody
(bottom right) showed a pattern that is typical of anti-
endomysium antibodies (EMAs), and of all the other
antibodies, attesting to their speciﬁcity to TG2.
DISCUSSION
In this study, given the reported derangement of the
intestinal immunity in type 1 diabetic patients (2,3,5) and
the association of type 1 diabetes and celiac disease (6–8),
we investigated the production and presence of anti-TG2
antibodies, which are a hallmark of celiac disease, in the
TABLE 2
Prevalence of IgA anti-TG2 mucosal deposits in the study
population
Patients
Presence of anti-TG2
mucosal deposits % Positivity
Type 1 diabetic patients
TG2
 11/14 78
TG
 11/19 58
Patients with untreated
celiac disease 12/12 100
Control subjects 4/28 14
Patients with IBD 3/18 16.6
Patients with food
allergies 0/9 0
TG2
 type 1 diabetic patients had increased serum levels of anti-TG2
antibodies; TG2
 type 1 diabetic patients had normal serum levels of
anti-TG2 antibodies.
TABLE 3
VH5 gene family–restricted IgA phage display libraries
VH5 gene family IgA phage display libraries
Type 1 diabetic TG2
 Type 1 diabetic TG2

Library code N1 N2 N3 N4 N5 N6 N7
Library size 3.1 
 10
6 3.2 
 10
6 1.6 
 10
6 4.1 
 10
6 6.3 
 10
6 4.6 
 10
6 2.6 
 10
6
Anti-TG2 antibodies 84 28 73 42 2 0 6
Data are the percentage of positive clones. VH5 gene family–restricted IgA phage display libraries from type 1 diabetes patient lymphocytes
were selected for human TG2. The library size represents the number of bacterial clones expressing an antibody fragment. After two rounds
of panning, 45 clones for each library were individually tested by ELISA for TG2. Only serologically TG2
 type 1 diabetic patients have a
signiﬁcant number of recombinant -human TG2 antibodies using the VH5 gene family.
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with normal jejunal architecture were included in this
study, which excluded patients with villous atrophy and a
diagnosis of overt celiac disease. The results obtained
show the presence of anti-TG2 antibodies in the jejunal
mucosa of most patients with type 1 diabetes. However, a
more precise analysis of the features of these antibodies,
particularly the use of the VH genes, has shown that only
in type 1 diabetic patients with serum titers of anti-TG2
antibodies that are higher than the cutoff do the anti-TG2
antibodies have the same features that they have in
patients with celiac disease.
The immunoﬂuorescence technique we used to detect
intestinal deposits of anti-TG2 antibodies (11) is based on
the colocalization of antibodies to IgA and to TG2; in this
study, we validated this immunoﬂuorescence technique
with the use of confocal microscopy to conﬁrm the
colocalization. We have previously shown the presence of
these deposits (25) in patients with villous atrophy as well
as in subjects who had normal mucosa but other signs
suggestive of potential celiac disease, such as the presence
of EMAs in the serum (17) or an increased density of IELs
expressing the  receptor (17). In the latter patients,
these deposits have been shown by others to predict the
future evolution to frank disease (15). In the potential
celiac disease patients, we observed that these deposits
were often observed in a patchy distribution and were less
thick (25). The patchy pattern has also been observed in
the patients with type 1 diabetes in this study. In fact, in
the type 1 diabetic patients with normal mucosa and a high
serum titer of anti-TG2 antibodies, these titers were still
lower than those in subjects with villous atrophy; these
lower titers and probably the lower antibody afﬁnity might
explain the patchy distribution and the thinner line of
intestinal deposits.
The presence of these antibodies at the intestinal level
strongly suggests that they are locally produced. As a
matter of fact, the intestinal production of these antibod-
ies has been demonstrated in patients with celiac disease
by means of organ culture (26) and by the detection and
measurement of these antibodies in intestinal juices (27)
and feces (26). The results obtained with the phage display
antibody libraries deﬁnitely support the above data on the
presence of deposits and local production of anti-TG2
antibodies in the intestine of type 1 diabetic patients. The
ﬁrst attempt, in which we aimed to construct and select
antibody libraries that used only the VH5 gene family,
yielded many clones isolated from type 1 diabetic patients
with a detectable serum titer of antibodies to TG2,
whereas very few VH5 antibodies were selected from type
1 diabetic patients without elevated serum antibodies to
TG2. This result is not in contrast with our previous
studies on celiac disease anti-TG2 antibody proﬁling, in
which we found that all the patients shared an atypical
VH5 gene family usage in making antibodies to TG2 (10).
However, in these patients, other antibodies belonging to
the VH1 and VH3 families that recognize a different
epitopic region are also produced. In this respect, the TG2
serologically negative type 1 diabetic patients do not
correspond to patients with celiac disease because very
few VH5 antibodies were selected. On the other hand, the
remarkable intestinal antibody response to TG2 revealed
by the whole antibody libraries from the TG2
 type 1
diabetic patients, although with a preferential use of the
VH3 family, again suggests a relationship with celiac
disease. Moreover, these antibodies, along with the VH1
and VH4 antibodies, were shown to recognize the endomy-
sial TG2 according to the EMA pattern that is typical for
the VH5 antibodies. The interpretation that this antibody
production might be gluten dependent is strengthened by
the number of antibodies to gliadin that were isolated from
all of the type 1 diabetic patient libraries but not from the
control subjects without celiac disease. We cannot predict
whether type 1 diabetic patients with a normal serum level
of anti-TG2 antibodies who show a strong anti-TG2 anti-
body intestinal response either are in a very early stage of
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0
10
20
30
40
50
60 celiac
T1DM
V Gene family
%
 
o
f
 
g
e
n
e
 
u
s
a
g
e
FIG. 2. Percentage of VH gene family usage in the recombinant
anti-TG2 antibodies selected from seven intestinal B lymphocytes of
type 1 diabetic patients (T1DM) and three intestinal B lymphocytes of
patients with celiac disease.
TABLE 4
Whole VH gene family IgA phage display libraries
Whole VH gene family IgA phage display libraries
Type 1 diabetic TG2
 Type 1 diabetic TG2

Control subjects without
celiac disease
Library code N1 N2 N3 N4 N5 N6 N7 H1 H2 H3
Library size 8.6 
 10
7 8.8 
 10
8 3.8 
 10
8 7.5 
 10
7 6.9 
 10
7 1.8 
 10
7 2.8 
 10
7 5.7 
 10
7 5.7 
 10
7 6 
 10
7
Anti-TG2 antibodies 86 88 73 46 71 68 86 10 3 0
Anti–-gliadin
antibodies 80 97 77 53 57 93 82 3 11 0
Data are the percentage of positive clones. IgA phage display libraries from the lymphocytes isolated from type 1 diabetes patients and
control subjects without celiac disease were constructed using all of the VH gene families. The libraries were selected for human TG2 and
-gliadin. After two rounds of selection, 45 clones for each type 1 diabetes library and 90 clones for each control library were individually
tested by ELISA for the corresponding antigen. All of the libraries from type 1 diabetic patients who were either serologically positive or
negative for TG2 show a high percentage of positive clones.
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addition, we do not know whether a possible shift in the
VH3-based antibody response to a VH5 response may be a
signiﬁcant step in the progression of the illness. Antigen
spreading by both antibody and T-cell epitopes is a well-
known feature of autoimmune diabetes, and we wonder
whether this is a characteristic of the anti-TG2 antibody
response as well. If the results that have been reported
here are conﬁrmed, the cloning of intestinal antibodies
could be considered a useful tool for investigating the
immunological background of both type 1 diabetes and
celiac disease. In a preliminary study (28), we found that
consumption of a gluten-free diet was beneﬁcial for type 1
diabetic patients and was paralleled by a change in the
proﬁle of the intestinal antibody response. In this respect,
the present study provides a more comprehensive inter-
pretation of the possible immunotoxic effect of gluten.
Intestinal anti-TG2 antibodies have also been noted in
the intestines of NOD mice (29). In NOD mice, the
presence of the antibodies in the gut is accompanied by
high antibody levels in the serum, but their presence is not
dependent on the presence of gluten in the diet. The same
could apply to type 1 diabetic patients who do not show
the same special use of the VH genes. We have not
investigated other autoimmune conditions, but we can
exclude the notion that the ﬁnding of the intestinal anti-
TG2 autoantibodies is simply related to HLA status or is
merely a consequence of intestinal inﬂammation.
It is difﬁcult to predict which functional effect could be
exerted by the anti-TG2 antibodies present in the gut of
type 1 diabetic patients. Studies conducted on antibodies
derived from patients with celiac disease suggest that they
at least partly inhibit enzymatic activity (30); furthermore,
it was recently found that they favor proliferation in the
epithelial compartment (31).
In conclusion, we have shown that the majority of
patients with type 1 diabetes have anti-TG2 antibodies in
their intestinal mucosa. The special use of the VH5 genes
in type 1 diabetic patients with serum positivity for anti-
endomysium suggests a gluten-dependent phenomenon
analogous to what has been found in celiac disease. These
patients belong to the spectrum of gluten sensitivity that
ranges from an abnormal immune response to frank
villous atrophy. More difﬁcult is the interpretation of the
ﬁnding of the intestinal anti-TG2 antibodies, not necessar-
ily using the VH5 genes, in those with an absence of a high
titer of these antibodies in the serum; in these patients, the
relationship with gluten is uncertain. It could be an
expression of autoimmunity, analogous to what has been
observed in NOD mice, and be included in the more
general derangement of the intestinal mucosal immunity
observed in type 1 diabetes. In addition, the raised density
of 
 IELs that has been observed in type 1 diabetes,
irrespective of the presence of high serum titers of anti-
TG2 antibodies, could be a feature of autoimmunity that
has also been observed in other autoimmune conditions
α-TG2 VH1 α-TG2 VH3
α-TG2 VH4 α-TG2 VH5
FIG. 3. Monkey esophagus sections stained with anti-TG2 scFv containing a VH1, VH3, and VH4 gene segment. An anti-TG2 VH5 scFv is shown as
a control. All of the scFvs recognize native TG2–anti-endomysium structures in the oesophagus muscularis mucosa according to the reticular
motif, which is similar to the results observed for serum anti-endomysium antibodies. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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molecular basis of the antibody response to TG2 will help
to interpret the observations reported here and, in partic-
ular, to understand to what extent the presence of these
antibodies and, in general, the derangement of the muco-
sal immunity is related to dietary gluten in type 1 diabetes.
ACKNOWLEDGMENTS
This work was supported by Fondazione Cariplo, Compag-
nia Sanpaolo, and the Italian Ministry of University and
Research (project “Intestino e autoimmunita `”).
No potential conﬂicts of interest relevant to this article
were reported.
REFERENCES
1. Mallone R, van Ender P. T cells in the pathogenesis of type 1 diabetes. Curr
Diab Rep 2008;8:101–106
2. Savilahti E, Ormala T, Sukkonen T, Sandini-Pohjavouri U, Kantele JM,
Arato A, Ilonen J, Åkerblom HK. Jejuna of patients with insulin-dependent
diabetes mellitus (IDDM) shows signs of immune activation. Clin Exp
Immunol 1999;116:70–77
3. Westerholm-Ormio M, Vaarala O, Pihkala P, Ilonen J, Savilahti E. Immu-
nologic activity in the small intestinal mucosa of pediatric patients with
type 1 diabetes. Diabetes 2003;52:2287–2295
4. Carratu ` R, Secondulfo M, De Magistris L, Iafusco D, Urio A, Cardone MG,
Pontoni G, Cartenì M, Prisco F. Altered intestinal permeability to mannitol
in diabetes mellitus type 1. J Pediatr Gastroenterol Nutr 1999;28:264–269
5. Auricchio R, Paparo F, Maglio M, Franzese A, Lombardi F, Valerio G,
Nardone G, Percopo S, Greco L, Troncone R. In vitro-deranged intestinal
immune response to gliadin in type 1 diabetes. Diabetes 2004;53:1680–1683
6. Maki M, Hallstrom O, Huupponen T, Vesikari T, Visakorpi JK. Increased
prevalence of coeliac disease in diabetes. Arch Dis Child 1984;59:739–742
7. Savilahti E, Simell O, Koskimies S, Rilva A, Akerblom HK. Coeliac disease
in insulin dependent diabetes mellitus. J Pediatr 1986;108:690–693
8. Sategna-Guidetti C, Grossa S, Pulitano R, Benaduce E, Dani FCarta Q.
Celiac disease and insulin dependent diabetes mellitus: screening in adult
population. Dig Dis Sci 1994;39:1633–1637
9. Sollid LM. Coeliac disease: dissecting a complex inﬂammatory disorder.
Nat Rev Immunol 2002;2:647–655
10. Marzari R, Sblattero D, Florian F, Tongiorgi E, Not T, Tommasini A,
Ventura A, Bradbury A. Molecular dissection of the tissue transglutami-
nase autoantibody response in celiac disease. J Immunol 2001;166:4170–
4176
11. Korponay-Szabo IR, Halttunen T, Szalai Z, Laurila K, Kiraly R, Kovacs JB,
Fesus L, Maki M. In vivo targeting of intestinal and extraintestinal
transglutaminase 2 by coeliac autoantibodies. Gut 2004;53:641–648
12. Troncone R, Franzese A, Mazzarella G, Paparo F, Auricchio R, Coto I,
Mayer M, Greco L. Gluten sensitivity in a subset of children with insulin
dependent diabetes mellitus. Am J Gastroenterol 2003;98:590–595
13. Troncone R, Paparo F, Mazzarella G, Maglio M, Iovine G, Mayer M, Greco
L, Auricchio S. The spectrum of gluten sensitivity. In Coeliac disease.
Auricchio S, Greco L, Maiuri L, Troncone R, Eds. Naples, Jean Gilder
Editions, 2000, p. 151–155
14. Maki M, Huopponen T, Holm K, Hallstrom O. Seroconversion of reticulin
autoantibodies predicts coeliac disease in insulin dependent diabetes
mellitus. Gut 1995;36:239–242
15. Salmi TT, Collin P, Jarvinen O, Haimila K, Partanen J, Laurila K, Korponay-
Szabo IR, Huhtala H, Reunala T, Maki M, Kaukinen K. Immunoglobulin A
autoantibodies against transglutaminase 2 in the small intestinal mucosa
predict forthcoming coeliac disease. Aliment Pharmacol Ther 2006;24:541–
552
16. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of celiac
disease: time for a standardized report scheme for pathologists. Eur J
Gastroenterol Hepatol 1999;11:1185–1194
17. Paparo F, Petrone E, Tosco A, Maglio M, Borrelli M, Salvati VM, Miele E,
Greco L, Auricchio S, Troncone R. Clinical, HLA, and small bowel
immunohistochemical features of children with positive serum anti-en-
domysium antibodies and architecturally normal small intestinal mucosa.
Am J Gastroenterol 2005;100:2294–2298
18. Sblattero D, Florian F, Azioni E, Ziberna F, Tommasini A, Not T, Ventura
A, Bradbury A, Marzari R. One-step cloning of anti tissue transglutaminase
scFv from subjects with celiac disease. J Autoimmun 2004;22:65–72
19. Sblattero D, Bradbury A. A deﬁnitive set of oligonucleotide primers for
amplifying human V regions. Immunotechnology 1998;3:271–278
20. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Grifﬁths AD, Winter
G. By-passing immunization: human antibodies from V-gene libraries
displayed on phage. J Mol Biol 1991;222:581–597
21. Silano M, De Vincenzi M. Bioactive antinutritional peptides derived from
cereal prolamins: a review. Nahrung 1999;43:175–184
22. Sblattero D, Berti I, Trevisiol C, Marzari R, Tommasini A, Bradbury A,
Fasano A, Ventura A, Not T. Human recombinant tissue transglutaminase
ELISA: an innovative diagnostic assay for celiac disease. Am J Gastroen-
terol 2000;95:1253–1257
23. Tomlinson IM, Williams SC, Corbett SJ, Cox JPL, Winter G: V BASE
Sequence Directory. Cambridge, U.K., Medical Research Council Centre
for Protein Engineering, 1996
24. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan
D. Identiﬁcation of tissue transglutaminase as the autoantigen of celiac
disease. Nat Med 1997;3:797–801
25. Tosco A, Maglio M, Paparo F, Rapacciuolo L, Sannino A, Miele E, Barone
MV, Auricchio R, Troncone R. Immunoglobulin A anti-tissue transglutami-
nase antibody deposits in the small intestinal mucosa of children with no
villous atrophy. J Pediatr Gastroenterol Nutr 2008;47:293–298
26. Picarelli A, Sabbatella L, Di Tola M, Di Cello T, Vetrano S, Anania MC.
Antiendomysial antibody detection in fecal supernatants: in vivo proof that
small bowel mucosa is the site of antiendomysial antibody production.
Am J Gastroenterol 2002;97:95–98
27. Mawhinney H, Love AH. Anti-reticulin antibody in jejunal juice in coeliac
disease. Clin Exp Immunol 1975;21:394–398
28. Sblattero D, Ventura A, Tommasini A, Cattin L, Martelossi S, Florian F,
Marzari R, Bradbury A, Not T. Cryptic gluten intolerance in type 1 diabetes:
identifying suitable candidates for a gluten free diet. Gut 2006;55:133
29. Sblattero D, Maurano F, Mazzarella G, Rossi M, Auricchio S, Florian F,
Ziberna F, Tommasini A, Not T, Ventura A, Bradbury A, Marzari R,
Troncone R. Characterization of the anti-tissue transglutaminase antibody
response in nonobese diabetic mice. J Immunol 2005;174:5830–5836
30. Esposito C, Paparo F, Caputo I, Rossi M, Maglio M, Sblattero D, Not T,
Porta R, Auricchio S, Marzari R, Troncone R. Anti-tissue transglutaminase
antibodies from coeliac patients inhibit transglutaminase activity both in
vitro and in situ. Gut 2002;5:177–181
31. Barone MV, Caputo I, Ribecco MT, Maglio M, Marzari R, Sblattero D,
Troncone R, Auricchio S, Esposito C. Humoral immune response to tissue
transglutaminase is related to epithelial cell proliferation in celiac disease.
Gastroenterology 2007;132:1245–1253
32. Valentino R, Savastano S, Maglio M, Paparo F, Ferrara F, Dorato M,
Lombardi G, Troncone R. Markers of potential coeliac disease in patients
with Hashimoto’s thyroiditis. Eur J Endocrinol 2002;146:479–483
33. Iltanen S, Holm K, Partanen J, Laippala P, Ma ¨ki M. Increased density of
jejunal 
 T cells in patients having normal mucosa—marker of operative
autoimmune mechanisms? Autoimmunity 1999;29:179–187
INTESTINAL ANTI-TG2 ANTIBODIES
1584 DIABETES, VOL. 58, JULY 2009